RGNX Curran Simpson sells $263K worth of shares
Oct 11, 2025, 4:35 AM
0.00%
What does RGNX do
REGENXBIO, a clinical-stage biotechnology company based in Rockville, Maryland, specializes in gene therapy using its NAV Technology Platform for retinal, neuromuscular, and neurodegenerative diseases. Its key therapies include ABBV-RGX-314, RGX-202, and RGX-121.
Curran Simpson sold 20,811 shares of RGNX on 9 October at $12.62 per share, worth a total of $263K. They now own 216,162 RGNX shares, or a 9% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.